WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100795

CAS#: 104987-11-3

Description: Tacrolimus, also known as FK-506, is an immunosuppressive drug used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and to lower the risk of organ rejection. It is also used in a topical preparation in the treatment of atopic dermatitis (eczema), severe refractory uveitis after bone marrow transplants, exacerbations of minimal change disease, TH2-mediated diseases such as Kimura's disease, and the skin condition vitiligo. FK-506 is a macrolide isolated from the fungus Streptomyces tsukubaensis.

Price and Availability


USD 150
USD 290
USD 820

USD 190
USD 350
USD 2450

USD 250
USD 460
USD 6950

Tacrolimus, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 2g may be 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 100795
Name: Tacrolimus
CAS#: 104987-11-3
Chemical Formula: C44H69NO12
Exact Mass: 803.48198
Molecular Weight: 804.02
Elemental Analysis: C, 65.73; H, 8.65; N, 1.74; O, 23.88

Synonym: FK 506, FK-506, FK506, fujimycin, fujimycin, Prograf, Protopic, Advagraf

IUPAC/Chemical Name: [3S [3R*[E(1S*,3S*,4S*)], 4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]] -5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone


InChi Code: InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33?,34-,36?,37-,38-,39+,40+,44+/m0/s1

SMILES Code: O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC=C)=O)=O)O[C@H](/C(C)=C/[C@H]4CC(OC)C(O)CC4)[C@H](C)[C@@H](O)CC3=O

Technical Data

White solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Penninga L, Penninga EI, Møller CH, Iversen M, Steinbrüchel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev. 2013 May 31;5:CD008817. doi: 10.1002/14651858.CD008817.pub2. Review. PubMed PMID: 23728681.

2: Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Komatsu N, Noguchi M. Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature. J Clin Exp Hematop. 2012;52(3):211-8. Review. PubMed PMID: 23269082.

3: Remitz A, Reitamo S. Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf. 2009 Jul;8(4):501-6. doi: 10.1517/14740330902969441 . Review. PubMed PMID: 19435404.

4: Sánchez-Pérez J. [Safety information for tacrolimus: present and future]. Actas Dermosifiliogr. 2008 Feb;99 Suppl 2:19-25. Review. Spanish. PubMed PMID: 18346426.

5: Torrelo A. [Topical tacrolimus in atopic dermatitis in children]. Actas Dermosifiliogr. 2008 Feb;99 Suppl 2:14-8. Review. Spanish. PubMed PMID: 18346425.

6: Ortiz de Frutos FJ. [Atopic dermatitis and tacrolimus in adults]. Actas Dermosifiliogr. 2008 Feb;99 Suppl 2:8-13. Review. Spanish. PubMed PMID: 18346424.

7: Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol. 2007 Nov;157(5):861-73. Epub 2007 Sep 13. Review. PubMed PMID: 17854353.

8: Sánchez-Pérez J. [Topical pimecrolimus and tacrolimus and the risk of cancer]. Actas Dermosifiliogr. 2007 Jun;98(5):312-7. Review. Spanish. PubMed PMID: 17555673.

9: van Dieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE, van der Woude CJ. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis. 2006 Apr;12(4):311-27. Review. PubMed PMID: 16633053.

10: Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol. 2005 Oct;153(4):701-5. Review. PubMed PMID: 16181449.

11: Dé Tran QH, Guay E, Chartier S, Tousignant J. Tacrolimus in dermatology. J Cutan Med Surg. 2001 Jul-Aug;5(4):329-35. Epub 2001 May 2. Review. PubMed PMID: 11907845.

12: Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002 Feb;46(2):228-41. Review. PubMed PMID: 11807435.

13: Woo M, Przepiorka D, Ippoliti C, Warkentin D, Khouri I, Fritsche H, Körbling M. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 1997 Dec;20(12):1095-8. Review. PubMed PMID: 9466284.